-
公开(公告)号：US20120189609A1
公开(公告)日：2012-07-26
申请号：US13392623
申请日：2010-08-27
CPC分类号： A61K38/484 , A61K9/0048 , A61K9/0051 , A61K45/06 , A61K47/12
摘要： The current invention relates to the improvement of trabeculectomy surgery. The improvement more specifically resides in an extended lifetime of the sclera-corneal drainage channel created by trabeculectomy surgery. The improvement is obtained by post-surgical administration of a plasmin or active derivative thereof in the form of topical eye drops alone, by anterior chamber injection alone, or by any combination of these.
摘要翻译： 本发明涉及小梁切除术手术的改进。 改进更具体地在于通过小梁切除术手术产生的巩膜 - 角膜引流通道的延长的使用寿命。 改善是通过手术后施用单独的局部眼药水的形式的纤溶酶或其活性衍生物，通过单独的前房注射或其任意组合来获得的。
-
公开(公告)号：US20100104530A1
公开(公告)日：2010-04-29
申请号：US12452356
申请日：2008-06-26
CPC分类号： C07K16/2869 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Monoclonal antibodies, in particular monoclonal antibodies to the VPAC1 receptor protein, compositions containing them and nucleic acid sequences encoding them. Host cells expressing said monoclonal antibodies, recombinant (expression) vectors and methods for producing said antibodies. Prevention or treatment of thrombocytopenia with antibodies to the VPAC1 receptor.
摘要翻译： 单克隆抗体，特别是VPAC1受体蛋白的单克隆抗体，含有它们的组合物和编码它们的核酸序列。 表达所述单克隆抗体的宿主细胞，重组（表达）载体和用于产生所述抗体的方法。 用VPAC1受体抗体预防或治疗血小板减少症。
-
公开(公告)号：US07875704B2
公开(公告)日：2011-01-25
申请号：US11909604
申请日：2006-03-24
IPC分类号： C07K16/00
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译： 本发明提供了针对PlGF及其片段和衍生物的更新的单克隆抗体，更具体地提供用于治疗和/或预防病理性血管生成的人源化抗体及其片段。
-
4.发明授权Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions 有权取代的芳基和杂芳基衍生物，其制备方法和用作药物组合物公开(公告)号：US07005437B2
公开(公告)日：2006-02-28
申请号：US10142699
申请日：2002-05-10
申请人： Henning Priepke , Uwe Ries , Herbert Nar , Wolfgang Wienen , Jean-Marie Stassen
发明人： Henning Priepke , Uwe Ries , Herbert Nar , Wolfgang Wienen , Jean-Marie Stassen
IPC分类号： A61K31/445 , A61K31/44 , A61K31/40 , C07D301/00 , C07D211/68
CPC分类号： C07D295/185 , C07C257/18 , C07C311/37 , C07C2601/08 , C07D207/20 , C07D295/192
摘要： The present invention relates to new substituted aryl and heteroaryl derivatives of general formula wherein A, Ar, n, X, Y1, Y2, Y3, Y4, R1 and R5 are defined as in claim 1, the prodrugs, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties. Thus, the compounds of the above general formula I wherein R5 does not contain a cyano group have, in particular, an antithrombotic effect and a selective factor Xa-inhibiting effect with generally improved compatibility. The compounds of the above general formula I wherein R5 contains a cyano group are valuable intermediate products for preparing the antithrombotic compounds of general formula I.
摘要翻译： 本发明涉及通式为“化学式id =”CHEM-US-00001“num =”000的新的取代的芳基和杂芳基衍生物
-
公开(公告)号：US08758748B2
公开(公告)日：2014-06-24
申请号：US12973155
申请日：2010-12-20
IPC分类号： A61K39/395
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译： 本发明提供了针对PlGF及其片段和衍生物的更新的单克隆抗体，更具体地提供用于治疗和/或预防病理性血管生成的人源化抗体及其片段。
-
公开(公告)号：US20110123525A1
公开(公告)日：2011-05-26
申请号：US12973155
申请日：2010-12-20
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to PlGF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译： 本发明提供了针对PlGF及其片段和衍生物的更新的单克隆抗体，更具体地提供用于治疗和/或预防病理性血管生成的人源化抗体及其片段。
-
7.发明授权Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals 有权双环杂环，其制备及其作为药物的用途
公开(公告)号：US6114532A
公开(公告)日：2000-09-05
申请号：US243200
申请日：1999-02-02
申请人： Uwe Ries , Norbert Hauel , Gerhard Mihm , Henning Priepke , Klaus Binder , Jean-Marie Stassen , Wolfgang Weinen , Rainer Zimmerman
发明人： Uwe Ries , Norbert Hauel , Gerhard Mihm , Henning Priepke , Klaus Binder , Jean-Marie Stassen , Wolfgang Weinen , Rainer Zimmerman
IPC分类号： C07D209/18 , C07D209/24 , C07D235/16 , C07D235/20 , C07D263/56 , C07D277/30 , C07D277/64 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/12 , C07D403/04 , C07D403/06 , C07D403/08 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12 , C07F9/6506 , A61K31/4184 , C07D413/06 , C07D307/01
CPC分类号： C07D263/56 , C07D209/18 , C07D209/24 , C07D235/16 , C07D235/20 , C07D277/30 , C07D277/64 , C07D401/04 , C07D401/06 , C07D401/08 , C07D401/12 , C07D403/04 , C07D403/08 , C07D403/12 , C07D405/12 , C07D417/04 , C07D417/12 , C07F9/65068
摘要： The present invention relates to 5-membered heterocyclic condensed benzoderivatives of formula ##STR1## wherein R.sub.a to R.sub.c, A, X and Y are defined as in claim 1, the tautomers, stereoisomers, mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable properties.The compounds of the above formula I wherein R.sub.c denotes a cyano group are valuable intermediates for preparing the other compounds of formula I, and the compounds of the above formula I wherein R.sub.c denotes one of the following amidino groups and the tautomers and stereoisomers thereof have valuable pharmacological properties, particularly an antithrombotic activity.
摘要翻译： 本发明涉及下式的5-元杂环稠合苯并衍生物：其中Ra至Rc，A，X和Y如权利要求1所定义，互变异构体，立体异构体，其混合物及其盐，特别是其与无机的生理学上可接受的盐 或具有有价值性质的有机酸或碱。 其中R c表示氰基的上式I化合物是制备其它式I化合物的有价值的中间体，其中R c表示以下脒基中的一种，其互变异构体和立体异构体具有有价值的上述式Ⅰ化合物 药理特性，特别是抗血栓活性。
-
公开(公告)号：US20080193455A1
公开(公告)日：2008-08-14
申请号：US11909604
申请日：2006-03-24
IPC分类号： A61K39/395 , C07K16/18 , G01N33/567 , A61P43/00 , A01K67/027 , C12N5/06
CPC分类号： C07K16/22 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24
摘要： The present invention provides novel monoclonal antibodies directed to P1GF and fragments and derivatives thereof, more particularly to humanized antibodies and fragments thereof for use in the treatment and/or prevention of pathological angiogenesis.
摘要翻译： 本发明提供了针对P1GF的新型单克隆抗体及其片段及其衍生物，更具体地提供用于治疗和/或预防病理性血管发生的人源化抗体及其片段。
-
9.发明授权Use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thromboisi 失效葡萄球菌激酶用于制备治疗动脉血栓形成的药物组合物
公开(公告)号：US5336495A
公开(公告)日：1994-08-09
申请号：US91885
申请日：1993-07-14
IPC分类号： A61K38/16 , A61K37/547
CPC分类号： A61K38/164
摘要： The present invention relates to the use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thrombosis, such as e.g. myocardial infarction. It is demonstrated that staphylokinase can be particularly useful as a thrombolytic agent for the lysis of platelet-rich clots. Furthermore it is demonstrated that staphylokinase, unlike streptokinase, does not induce antibody induction upon repeated administration.
摘要翻译： 本发明涉及葡萄球菌激酶在制备用于治疗动脉血栓形成的药物组合物中的用途， 心肌梗死 证明葡萄球菌激酶可以特别用作裂解血小板富集血块的血栓溶解剂。 此外，证明葡萄球菌激酶与链激酶不同，在重复给药时不诱导抗体诱导。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.022 秒)
